Microbiological activity of thiamphenicol and thiamphenicol glycinate acetylcysteinate against clinically significant microorganisms and their biofilms | CMAC

Microbiological activity of thiamphenicol and thiamphenicol glycinate acetylcysteinate against clinically significant microorganisms and their biofilms

Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(1):31-39

​ Karpova E.V., Kolchanova N.E., Petrovskaya T.A., Tapalskiy D.V.
10.36488/cmac.2024.1.31-39
thiamphenicol chloramphenicol N-acetylcysteine Streptococcus pneumoniae Staphylococcus aureus Klebsiella pneumoniae biofilm
Section
Antimicrobials
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(1):31-39

Objective.

To determine the minimum inhibitory concentrations of thiamphenicol and thiamphenicol glycinate acetylcysteinate against clinically significant microorganisms and determine their efficacy against microbial biofilms.

Materials and Methods.

This study included 48 clinical strains isolated from the sputum of patients with respiratory tract infections (16 S. pneumoniae, K. pneumoniae and S. aureus strains). Antimicrobial susceptibility testing was performed using broth microdilution method. Biofilm formation culturing with antibiotics, N-acetylcysteine and their combinations was assessed in Mueller-Hinton broth and brain heart broth in 96-well plates. Biofilms are fixed with 2,5% glutaraldehyde solution, stained with 0,25% crystal violet solution, which is extracted by 33% acetic acid solution.

Results.

The MIC of thiamphenicol and thiamphenicol glycinate acetylcysteinate (in terms of thiamphenicol) were the same for 87,5% of strains. Thiamphenicol and thiamphenicol glycinate acetylcysteinate have been confirmed high antimicrobial activity against S. pneumoniae strains (MIC50 0,5 mg/l, MIC90 1-2 mg/l). Cultivation with chloramphenicol, thiamphenicol, thiamphenicol glycinate acetylcysteinate, combination of chloramphenicol and thiamphenicol with N-acetylcysteine contributed to significant reduction in the optical density of S. pneumoniae biofilms. Thiamphenicol increased biofilm formation in some resistant S. aureus and K. pneumoniae. Combination based on N-acetylcysteine neutralized this effect.

Conclusions.

Potentiation of antibacterial activity of thiamphenicol by N-acetylcysteine against S. pneumoniae biofilms has been shown.

Karpova E.V.

Gomel State Medical University, Gomel, Belarus

Kolchanova N.E.

Gomel State Medical University, Gomel, Belarus

Tatyana A. Petrovskaya

Gomel State Medical University, Gomel, Belarus

Dmitry V. Tapalskiy

Institute of Physiology of the National Academy of Sciences of Belarus, Minsk, Belarus

  • 1. Lombardi A., Drago L., De Vecchi E., Mombelli B., Gismondo M. Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae. Arzneimittelforschung. 2001;51(3):264-267. DOI: 10.1055/s-0031-1300034
  • 2. O’Grady F, Pearson N., Dennis C. Thiamphenicol and chloramphenicol: an in vitro comparison with particular reference to bactericidal activity. Chemotherapy. 1980;26(2):116-120. DOI: 10.1159/000237892
  • 3. Ivanchik N.V., Sukhorukova М.V., Chagaryan А.N., Trushin I.V., Dekhnich А.V., Kozlov R.S. In vitro activity of thiamphenicol against Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus pyogenes clinical isolates. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2021;23(1):92-99. Russian. DOI: 10.36488/cmac.2021.1.92-99
  • 4. Drago L., De Vecchi E., Fassina M., Mombelli B., Tocalli L., Gismondo M. Comparative in vitro activity of thiamphenicol-glycinate and thiamphenicol-glycinate-acetylcysteinate and other antimicrobials against respiratory pathogens. Arzneimittelforschung. 2001;51(4):315-324. DOI: 10.1055/s-0031-1300044
  • 5. Belevskiy A., Knyazheskaya N. Thiamphenicol glycinate acetylcysteinate for the treatment of acute and chronic pulmonary diseases. Practical pulmonology. 2017;3:122-126. Russian.
  • 6. Serra A., Schito G., Nicoletti G., Fadda G. A therapeutic approach in the treatment of infections of the upper airways: thiamphenicol glycinate acetylcysteinate in sequential treatment (systemic-inhalatory route). Int J Immunopathol Pharmacol. 2007;20(3):607-617. DOI: 10.1177/039463200702000319
  • 7. Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013;136:1-51. DOI: 10.1111/apm.12099
  • 8. Kostakioti M., Hadjifrangiskou M., Hultgren S. Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold Spring Harb Perspect Med. 2013;3(4):a010306. DOI: 10.1101/cshperspect.a010306
  • 9. Lebeaux D., Ghigo J., Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 2014;78(3):510-543. DOI: 10.1128/MMBR.00013-14
  • 10. Akbarian M., Chen S., Kianpour M., Farjadian F., Tayebi L., Uversky V. A review on biofilms and the currently available antibiofilm approaches: matrix-destabilizing hydrolases and anti-bacterial peptides as promising candidates for the food industries. Int J Biol Macromol. 2022;219:1163-1179. DOI: 10.1016/j.ijbiomac.2022.08.192
  • 11. Amankwah S., Abdella K., Kassa T. Bacterial biofilm destruction: a focused review on the recent use of phagebased strategies with other antibiofilm agents. Nanotechnol Sci Appl. 2021;14:161-177. DOI: 10.2147/NSA.S325594
  • 12. Zhang L., Bera H., Wang H., Wang J., Guo Y., Shi C., et al. Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. Int J Pharm. 2022;616:121507. DOI: 10.1016/j.ijpharm.2022.121507
  • 13. Dieltjens L., Appermans K., Lissens M., Lories B., Kim W., Van der Eycken E., et al. Inhibiting bacterial cooperation is an evolutionarily robust anti-biofilm strategy. Nat Commun. 2020;11:107. DOI: 10.1038/s41467-019-13660-x
  • 14. ISO 20776-1:2006 «Clinical laboratory testing and in vitro diagnostic test systems – Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices» – Part 1 : Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases.
  • 15. Stepanovic S., Vukovic D., Hola V., Di Bonaventura G., Djukic S., Cirković I., et al. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS. 2007;115(8):891-899. DOI: 10.1111/j.1600-0463.2007
  • 16. Rebrova O.Yu. Statistical analysis of medical data. Using the Statistica software package. M.: Media Sphera, 2002. 305 p. Russian.
  • 17. Marchese A., Debbia E., Tonoli E., Gualco L., Schito A. In vitro activity of thiamphenicol against multiresistant Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in Italy. J Chemother. 2002;14:554-561. DOI: 10.1179/joc.2002.14.6.554
  • 18. Albini E., Belluco G., Berton M., Schioppacassi G., Ungheri D. In vitro antibacterial activity of thiamphenicol glycinate acetylcysteinate against respiratory pathogens. Arzneimittelforschung. 1999;49(6):533-537. DOI: 10.1055/s-0031-1300456
  • 19. Ciofu O., Moser C., Jensen P., Hoiby N. Tolerance and resistance of microbial biofilms. Nat Rev Microbiol. 2022;20(10):621-635. DOI: 10.1038/s41579-022-00682-4
  • 20. Domenech M., Sempere J., de Miguel S., Yuste J. Combination of antibodies and antibiotics as a promising strategy against multidrug-resistant pathogens of the respiratory tract. Front Immunol. 2018;9:2700. DOI: 10.3389/fimmu.2018.02700
  • 21. Pérez-Giraldo C., Rodríguez-Benito A., Morán F., Hurtado C., Blanco M., Gómez-García A. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob Chemother. 1997;39:643-646. DOI: 10.1093/jac/39.5.643
  • 22. Domenech M., Garcia E. N-Acetyl-L-cysteine and cysteamine as new strategies against mixed biofilms of nonencapsulated Streptococcus pneumoniae and nontypeable Haemophilus influenzae. Antimicrob Agents Chemother. 2017;61:e01992-16. DOI: 10.1128/AAC.01992-16
  • 23. Zhao T., Liu Y. N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiol. 2010;10:140. DOI: 10.1186/1471-2180-10-140
  • 24. Drago L., De Vecchi E., Mattina R., Romanò C. Activity of N-acetyl-L-cysteine against biofilm of Staphylococcus aureus and Pseudomonas aeruginosa on orthopedic prosthetic materials. Int J Artif Organs. 2013;36:39-46. DOI: 10.5301/ijao.5000135
  • 25. Domenech M., Pedrero-Vega E., Prieto A., Garcia E. Evidence of the presence of nucleic acids and beta-glucan in the matrix of non-typeable Haemophilus influenzae in vitro biofilms. Sci Rep. 2016;6:36424. DOI: 10.1038/srep36424
  • 26. Blasi F., Page C., Rossolini G., Pallecchi L., Matera M., Rogliani P., Cazzola M. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190-197. DOI: 10.1016/j.rmed.2016.06.015
  • 27. Llamosí M., Sempere J., Coronel P., Gimeno M., Yuste J., Domenech M. Combination of cefditoren and n-acetyll-cysteine shows a synergistic effect against multidrugresistant Streptococcus pneumoniae biofilms. Microbiol Spectr. 2022;10(6):e0341522. DOI: 10.1128/spectrum.03415-22
  • 28. Macchi A., Ardito F., Marchese A., Schito G.C., Fadda G. Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms. J Chemother. 2006;18(5):507-513. DOI: 10.1179/joc.2006.18.5.507
Views
0 Abstract
0 PDF
0 Crossref citations
Shared